









Markets
/
Stocks
/
nasdaq-upc
/

Universe Pharmaceuticals Inc

UPC

4.490USD

+0.340+8.19%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.53MMarket Cap

--P/E TTM



Universe Pharmaceuticals Inc

4.490

+0.340+8.19%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

135 / 175

Overall Ranking

612 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.

Growing

The company is in a growing phase, with the latest annual income totaling USD 23.02M.

Overvalued

The company’s latest PE is 0.00, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.73K shares, decreasing 79.59% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84. Its latest quarterly revenue reached 10.14M, representing a year-over-year decrease of 26.74%, while its net profit experienced a year-over-year decrease of 174.57%.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.80, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 0.00, which is -11.11% below the recent high of 0.00 and 1340.74% above the recent low of -0.03.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 135/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.07, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 5.18 and the support level at 3.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.07

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.144

Buy

RSI(14)

62.865

Neutral

STOCH(KDJ)(9,3,3)

36.730

Neutral

ATR(14)

0.752

High Vlolatility

CCI(14)

279.077

Overbought

Williams %R

66.379

Sell

TRIX(12,20)

0.586

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.204

Buy

MA10

4.073

Buy

MA20

3.843

Buy

MA50

3.730

Buy

MA100

4.079

Buy

MA200

10.215

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 0.66%, representing a quarter-over-quarter decrease of 92.51%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sununion Holding Group Ltd

3.47K

Sabby Management, LLC

-100.00%

Anson Funds Management LP.

-100.00%

Morgan Stanley & Co. LLC

-100.00%

MML Investors Services, LLC

-100.00%

Quadrature Capital LLP

-100.00%

Virtu Americas LLC

-100.00%

Geode Capital Management, L.L.C.

-100.00%

Two Sigma Investments, LP

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.92, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.47. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.